BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL—INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDY

作者
Matthew L. Ulrickson,David Bernard Miklos,Richard Thomas Maziarz,Caron Alyce Jacobson,Iris Isufi,Monalisa Ghosh,Miguel‐Angel Perales,Matthew Alexander Lunning,Nancy M. Hardy,Anna Wijatyk,Marek Ancukiewicz,Mrs. Madhavi Nallewar,K. C. Coleman,Bethany Cheree Prudner,Esther Eromosele,Remiguisz Kaleta,Nirav Niranjan Shah
出处
期刊:Hematological Oncology [Wiley]
卷期号:41 (S2): 147-147
标识
DOI:10.1002/hon.3163_96
摘要

Background: DALY II USA is the first multicenter trial of fresh, bispecific targeted CD20/CD19, chimeric antigen receptor (CAR) T-cell therapy for patients (pts) with R/R diffuse large B-cell lymphoma (DLBCL). While CD19 CAR T-cell therapy is an established treatment for pts with R/R DLBCL, relapse remains a clinical challenge. One proposed mechanism of resistance is either loss of epitope, recognition, or downregulation of the CD19 receptor. To improve outcomes, dual targeting of B-cell receptors has been proposed. Reported here is the preplanned interim futility analysis after treatment of 22 evaluable pts. Aim: To assess safety and efficacy of dual CAR-T therapy with zamtocabtagene autoleucel (zamto-cel) administered fresh in R/R DLBCL. Methods: Eligible pts were >18 y, ECOG PS 0–1, with R/R DLBCL after ≥2 prior lines of systemic therapy. No bridging chemotherapy was allowed. Apheresis material was shipped fresh without cryopreservation to a central manufacturing site. A fixed 12-day process of CAR-T production was performed using the CliniMACS Prodigy® (Miltenyi Biotec). A single infusion of 2.5x106 cells/kg fresh zamto-cel was administered after lymphodepletion which was initiated during manufacturing to facilitate a fresh infusion. Evaluation of response rate is the primary objective of this study. Results: As of 1 September 2022, 28 pts have enrolled (All treated) with 22 evaluable per protocol. Most (69%) of treated patients presented advanced disease with IPI score of at least 3 and abnormal baseline LDH and 28% were previously treated with CD19 and or CD79 targeting agents. Six pts were not included in the primary efficacy analysis. One received a frozen product and 5 received a non-conforming fresh product. Per Independent Radiology Committee (IRC) 18 (82%) of 22 evaluable pts had either complete (CR—46%) or partial response (PR—36%) exceeding the preplanned futility threshold. The response rate in the evaluable set was similar to that in the all-treated population (Tbl. 1). Post-progression biopsies were available in 5 pts. There was no isolated CD19 loss, but 1pt had dual target loss CD19+CD20 in relation to the pre-treatment status. PFS at 6 months for evaluable pts was 64% and 61% for all treated. The treatment was well tolerated. Among all 28 treated pts., there were no grade 3–4 CRS events and only two transient and reversible Grade 3 ICANS (9%). There was no treatment-related mortality. Summary/Conclusion: The prespecified efficacy threshold of zamto-cel was exceeded in the interim analysis Treatment demonstrated a favorable safety profile, with promising ORR and PFS in advanced DLBCL population often pre-treated with agents not available in previous similar studies. We also demonstrate the feasibility of a rapid manufacturing process with 100% fresh infusion in eligible pts. Encore Abstract—previously submitted to EHA 2023 Keywords: aggressive B-cell non-Hodgkin lymphoma, cellular therapies, immunotherapy No conflicts of interests pertinent to the abstract.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三的应助被会飞的鱼采纳,获得10
刚刚
三心草完成签到 ,获得积分10
刚刚
天天向上的应助被小赵采纳,获得10
刚刚
达达完成签到 ,获得积分10
刚刚
阿辉发布了新的文献求助10
1秒前
昭奚完成签到,获得积分10
1秒前
shaoshao86完成签到,获得积分10
1秒前
demi2333完成签到,获得积分10
1秒前
元谷雪完成签到,获得积分10
2秒前
英吉利25发布了新的文献求助10
2秒前
2秒前
虚幻的白秋完成签到,获得积分10
2秒前
2秒前
li完成签到 ,获得积分10
2秒前
2秒前
liusanshi发布了新的文献求助10
2秒前
2秒前
2秒前
yyyy完成签到,获得积分10
3秒前
天天快乐的应助被幸福的襄采纳,获得10
3秒前
Tuotuo完成签到 ,获得积分10
3秒前
gao完成签到,获得积分10
4秒前
笑笑笑先生完成签到,获得积分10
4秒前
苗条元柏完成签到,获得积分10
4秒前
4秒前
学术新星完成签到,获得积分10
4秒前
4秒前
zhao完成签到,获得积分10
4秒前
应急食品完成签到,获得积分10
5秒前
小小小先生的应助被科研人采纳,获得10
5秒前
Jiannuk完成签到,获得积分10
5秒前
gulu完成签到,获得积分20
5秒前
优雅的怀莲完成签到,获得积分10
5秒前
6秒前
小蘑材完成签到,获得积分10
6秒前
PsyQin完成签到,获得积分10
6秒前
六边形猪宝完成签到 ,获得积分10
6秒前
舒心橘子完成签到,获得积分10
6秒前
赤练仙子发布了新的文献求助10
7秒前
Puddingo完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105